Published : 12 May 2023
A Portland based Biotech has appointed Aagami to support their strategic investment and partnering needs.
The CEO of client company has known Aagami for over a decade and has awarded assignments earlier also while in other companies.
Client is a drug discovery and development company focused on first-in-class new chemical entities (NCEs) for the treatment of arrhythmia and heart failure.
· Lead compound EB3019 is an oral small molecule modulator of mutant RyR2 for the treatment of CPVT-1.
· MoA: EB3019 modulates mutated RyR2 channels to reduce dysfunctional diastolic Ca2+ ion leakage from the sarcoplasmic reticulum (SR).
· Efficacy: >40% patients have a measurable benefit on ETT
· Increases the exercise level reached before first arrhythmia by >20% at 30 days, with a sustained effect at 6 months and/or,
· Reduces the number of arrhythmias on exercise stress testing by >50% • Safety: Mild GI effects.
If you would like to know more about this partnering opportunity, please contact us.